This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

64/100

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Clinical trials

Topic: Amyloid, tau and blood-test diagnosis

Results Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females). No benefits were demonstrated for secondary clinical end points. From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase (P = .04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fleisher, A. S., Munsie, L., Mancini, M., Cheng, Y.-J., Guo, J., Nuthall, H., et al. (2026). Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.12768

Vancouver

Fleisher AS, Munsie L, Mancini M, Cheng Y.-J, Guo J, Nuthall H, et al. Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.12768. PMID: 42441396.

BibTeX

@article{fleisher2026-42441396,
  author  = {Fleisher, Adam S and Munsie, Leanne and Mancini, Michele and Cheng, Yun-Ju and Guo, Jiaying and Nuthall, Hugh and Otero, Diana Svaldi and Kotari, Vikas and others},
  title   = {{Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2026},
  doi     = {10.1001/jama.2026.12768},
  pmid    = {42441396},
  url     = {https://doi.org/10.1001/jama.2026.12768}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females).
No benefits were demonstrated for secondary clinical end points.
From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase (P = .04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe.

Why it matters

In this phase 2 trial, the drug ceperognastat showed no benefits on secondary clinical endpoints in people with early symptomatic Alzheimer's disease. A statistically significantly smaller increase in a PET tau measure was seen only in the 3 mg group in one brain region, which does not by itself show clinical benefit.

New to this subject? Start with our plain-English guide: Registered clinical trials →

Study details

Study designphase-2-trial
Participants327
Effect sizeDisease progression ratio vs placebo on iADRS at 100 weeks: 0.84 (95% CrI 0.66-1.04) for 0.75 mg; 1.32 (95% CrI 1.10-1.58) for 3 mg
Evidence strengthNull-result

Limitations

Phase 2 with a Bayesian disease-progression primary endpoint; excluded people with high tau load; 100-week follow-up may be short for a tau-modifying mechanism.

How this study scored 64/100

Published in a top-tier journal, and it is a mid-stage phase 2 trial. We have no data on senior author's track record and free to read, so those were left out: it earned 60 of the 94 points we could judge it on, which is 64 out of 100.

Component	Points	Why
Journal tier	10 / 10	Tier 1 — top-tier general journal (JAMA)
Journal's citation record	4 / 4	JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29)
Study design	8 / 12	A mid-stage phase 2 trial
Strength of evidence	3 / 5	Rated “null-result” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	2 / 4	327 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	1 / 2	Randomised (as stated in the record)
Times cited	2 / 7	Cited 5 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.5 citations a year over 2 year(s) since 2026
Impact for its field and year	5 / 6	Cited 20.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Oskar Hansson holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record	1 / 3	Eli Lilly (United States): institution h-index 744 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 42441396)
Free to read	— / 2	Access not recorded — left out of this score
Points	60 / 94	Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 60 of the 94 points we could judge it on is 64 out of 100.
Total	64 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Clinical trials

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Clinical trials

See all studies in Clinical trials →